Abstract
The goal of antiviral treatment for chronic hepatitis B (CHB) is to reduce the risk of liver-related complications, including liver cirrhosis, hepatic decompensation, and hepatocellular carcinoma (HCC). It is not possible to eliminate hepatitis B virus from the host with currently available antiviral treatments; hence, a realistic goal is to decrease the risk of HCC as much as possible with an appropriate and timely antiviral treatment. For the past decades, real-world evidence has enlarged the field of CHB research. Presently, there is mounting evidence that randomized clinical trials are not technically and ethically possible to conduct. In this review, we focus on secondary prevention by antiviral treatment in patients with CHB, mainly based on real-world evidence.
| Original language | English |
|---|---|
| Article number | 21 |
| Journal | Hepatoma Research |
| Volume | 7 |
| DOIs | |
| State | Published - 2021 |
Bibliographical note
Publisher Copyright:© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Antiviral agent
- Hepatitis B virus
- Hepatocellular carcinoma
Fingerprint
Dive into the research topics of 'Optimize nucleot(S)ide analogues’ to prevent hepatocellular carcinoma in patients with chronic hepatitis b: A lesson from real-world evidence'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver